Stella T. Tsui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stella T. Tsui has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Aurora D. Pryor
Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook, New York
5 shared publicationsJie Yang
Department of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York
5 shared publicationsKonstantinos Spaniolas
Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook, New York
5 shared publicationsXiaoyue Zhang
Department of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York
4 shared publicationsSalvatore Docimo
Division of Bariatric, Foregut and Advanced Gastrointestinal Surgery, Department of Surgery, Stony Brook University Medical Center, Stony Brook, New York
3 shared publications- Christina Liu
Weinberg College of Arts and Sciences, Northwestern University, Evanston, IL, 60208, USA
2 shared publications
Latest Publications
- Open Access
- 19 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109420
Utilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers
- 19 April 2026
- Published by Elsevier in Lung Cancer
- Vol. 216, 109420
Open AccessUtilization of invasive mediastinal nodal staging and prevalence of occult nodal disease in patients with synchronous primary lung cancers
- Open Access
Prognosis from Pixels: A Vendor-Protocol-Specific CT-Radiomics Model for Predicting Recurrence in Resected Lung Adenocarcinoma
Background: Radiomics can provide quantitative descriptors of tumor phenotype, but translation is often limited by feature instability across scanners and protocols. We aimed to develop and internally validate a protocol-specific CT-radiomics model using preoperative imaging to predict 5-year recurrence in patients with stage I lung adenocarcinoma after complete surgical resection. Methods: The retrospective study included 270 patients with completely resected stage I lung adenocarcinoma from January 2010–December 2021, among whom 23 (8.5%) experienced recurrence within five years. Radiomic features were extracted from routine preoperative CT scans. After preprocessing to remove highly constant and highly correlated features, the Synthetic Minority Over-sampling Technique addressed class imbalance in the training set. Recursive Feature Elimination identified the most predictive radiomic features. An XGBoost classifier was trained using optimized hyperparameters identified through RandomizedSearchCV with cross-validation. Model performance was evaluated using the ROC curve and predictive metrics. Results: Five radiomic features differed significantly between recurrence groups (p = 0.007 to <0.001): Shape Sphericity, first-order 90Percentile, GLCM Autocorrelation, GLCM Cluster Shade, and GLDM Large Dependence Low Gray Level Emphasis. The radiomics model showed excellent discriminatory ability with AUC values of 0.99 (95% CI: 0.98–1.00), 0.97 (95% CI: 0.91–1.00), and 0.96 (95% CI: 0.85–1.00) on the training, validation, and test sets, respectively. On the test set, the model achieved sensitivity of 100% (95% CI: 51–100%), specificity of 94% (95% CI: 81–98%), PPV of 67% (95% CI: 30–90%), NPV of 100% (95% CI: 90–100%), and overall accuracy of 95% (95% CI: 83–99%). Conclusions: Under protocol-homogeneous imaging conditions, CT radiomics accurately predicted recurrence in patients with completely resected stage I lung adenocarcinoma. External multi-vendor validation is needed before broader deployment.
Open AccessPrognosis from Pixels: A Vendor-Protocol-Specific CT-Radiomics Model for Predicting Recurrence in Resected Lung Adenocarcinoma
Background: Radiomics can provide quantitative descriptors of tumor phenotype, but translation is often limited by feature instability across scanners and protocols. We aimed to develop and internally validate a protocol-specific CT-radiomics model using preoperative imaging to predict 5-year recurrence in patients with stage I lung adenocarcinoma after complete surgical resection. Methods: The retrospective study included 270 patients with completely resected stage I lung adenocarcinoma from January 2010–December 2021, among whom 23 (8.5%) experienced recurrence within five years. Radiomic features were extracted from routine preoperative CT scans. After preprocessing to remove highly constant and highly correlated features, the Synthetic Minority Over-sampling Technique addressed class imbalance in the training set. Recursive Feature Elimination identified the most predictive radiomic features. An XGBoost classifier was trained using optimized hyperparameters identified through RandomizedSearchCV with cross-validation. Model performance was evaluated using the ROC curve and predictive metrics. Results: Five radiomic features differed significantly between recurrence groups (p = 0.007 to <0.001): Shape Sphericity, first-order 90Percentile, GLCM Autocorrelation, GLCM Cluster Shade, and GLDM Large Dependence Low Gray Level Emphasis. The radiomics model showed excellent discriminatory ability with AUC values of 0.99 (95% CI: 0.98–1.00), 0.97 (95% CI: 0.91–1.00), and 0.96 (95% CI: 0.85–1.00) on the training, validation, and test sets, respectively. On the test set, the model achieved sensitivity of 100% (95% CI: 51–100%), specificity of 94% (95% CI: 81–98%), PPV of 67% (95% CI: 30–90%), NPV of 100% (95% CI: 90–100%), and overall accuracy of 95% (95% CI: 83–99%). Conclusions: Under protocol-homogeneous imaging conditions, CT radiomics accurately predicted recurrence in patients with completely resected stage I lung adenocarcinoma. External multi-vendor validation is needed before broader deployment.
- 1 March 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (3) , 489-497
Hospitalizations and emergency department visits in heart failure patients after bariatric surgery
- 1 March 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (3) , 489-497
Hospitalizations and emergency department visits in heart failure patients after bariatric surgery
- 1 February 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (2) , 249-255
Health disparity in access to bariatric surgery
- 1 February 2021
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 17 (2) , 249-255
Health disparity in access to bariatric surgery
- 1 October 2020
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 16 (10) , 1586-1595
Development of cancer after bariatric surgery
- 1 October 2020
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 16 (10) , 1586-1595
Development of cancer after bariatric surgery
- 26 August 2020
- Published by Springer Nature in Surgical Endoscopy
- Vol. 35 (8) , 4267-4274
The risk of female-specific cancer after bariatric surgery in the state of New York
Background Obesity is a known risk factor for many cancers. Although bariatric surgery has been associated with a decrease in the risk of developing cancer, data on the effect of bariatric surgery on female-specific cancers are limited. This study aimed to assess the impact of bariatric interventions on the development of endometrial, ovarian and breast cancer. Methods The New York Statewide Planning and Research Cooperative System database was used to identify all female patients without a pre-existing cancer diagnosis who had a diagnosis of obesity between 2006 and 2012. The risk of having female-specific cancer diagnosis in patients who underwent bariatric surgery were compared with those who had no bariatric interventions using multivariable proportional sub-distribution hazard regression analysis. Subsequent cancer diagnoses were followed up to 2016. Results We identified 55,781 and 247,102 obese female patients who had and did not have bariatric surgery, respectively. The overall incidence of female-specific cancer was 2.69% and 2.09% for the non-surgery and surgery groups, respectively (p < 0.0001). Surgery patients were less likely to develop female-specific cancers [hazard ratio (HR) 0.78; 95% CI 0.73–0.83; p < 0.0001]. Patients undergoing Roux-en-Y gastric bypass had a lower risk of developing female-specific cancer than laparoscopic sleeve gastrectomy (HR 0.66; 95% CI 0.51–0.87; p = 0.0056) and laparoscopic adjustable gastric banding (HR 0.83; 95% CI 0.69–0.99; p = 0.0056) patients. Conclusions Patients undergoing bariatric surgery have a lower incidence of endometrial, female breast and ovarian cancer than non-surgery obese patients. These data suggest that bariatric interventions may reduce the risk of female-specific cancers. Graphic abstract
- 26 August 2020
- Published by Springer Nature in Surgical Endoscopy
- Vol. 35 (8) , 4267-4274
The risk of female-specific cancer after bariatric surgery in the state of New York
Background Obesity is a known risk factor for many cancers. Although bariatric surgery has been associated with a decrease in the risk of developing cancer, data on the effect of bariatric surgery on female-specific cancers are limited. This study aimed to assess the impact of bariatric interventions on the development of endometrial, ovarian and breast cancer. Methods The New York Statewide Planning and Research Cooperative System database was used to identify all female patients without a pre-existing cancer diagnosis who had a diagnosis of obesity between 2006 and 2012. The risk of having female-specific cancer diagnosis in patients who underwent bariatric surgery were compared with those who had no bariatric interventions using multivariable proportional sub-distribution hazard regression analysis. Subsequent cancer diagnoses were followed up to 2016. Results We identified 55,781 and 247,102 obese female patients who had and did not have bariatric surgery, respectively. The overall incidence of female-specific cancer was 2.69% and 2.09% for the non-surgery and surgery groups, respectively (p < 0.0001). Surgery patients were less likely to develop female-specific cancers [hazard ratio (HR) 0.78; 95% CI 0.73–0.83; p < 0.0001]. Patients undergoing Roux-en-Y gastric bypass had a lower risk of developing female-specific cancer than laparoscopic sleeve gastrectomy (HR 0.66; 95% CI 0.51–0.87; p = 0.0056) and laparoscopic adjustable gastric banding (HR 0.83; 95% CI 0.69–0.99; p = 0.0056) patients. Conclusions Patients undergoing bariatric surgery have a lower incidence of endometrial, female breast and ovarian cancer than non-surgery obese patients. These data suggest that bariatric interventions may reduce the risk of female-specific cancers. Graphic abstract
- 21 August 2019
- Published by Springer Nature in Surgical Endoscopy
- Vol. 34 (7) , 3110-3117
Association of revisions or conversions after sleeve gastrectomy with annual bariatric center procedural volume in the state of New York
Although bariatric center procedural volume has been associated with early perioperative safety, data on the effect of such volume and long-term outcomes after sleeve gastrectomy (SG) are limited. This study aims to examine the relationship between annual bariatric center SG volume and the incidence of revisions or conversions (RC) after SG.
- 21 August 2019
- Published by Springer Nature in Surgical Endoscopy
- Vol. 34 (7) , 3110-3117
Association of revisions or conversions after sleeve gastrectomy with annual bariatric center procedural volume in the state of New York
Although bariatric center procedural volume has been associated with early perioperative safety, data on the effect of such volume and long-term outcomes after sleeve gastrectomy (SG) are limited. This study aims to examine the relationship between annual bariatric center SG volume and the incidence of revisions or conversions (RC) after SG.
- Open Access
- 2 September 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-7
Second-generation inhibitors of Bruton tyrosine kinase
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.
- 2 September 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-7
Open AccessSecond-generation inhibitors of Bruton tyrosine kinase
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported. The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib. This review summarizes the clinical development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.
- Open Access
- 22 July 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-5
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. Resistance to AZD9291 has been described. C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors. This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.
- 22 July 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-5
Open AccessEGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer
T790M mutation is the most common mechanism for resistance to first- and second-generation tyrosine kinase inhibitors (TKI) for epidermal growth factor receptor (EGFR). Several third-generation EGFR mutant selective TKIs are being explored to conquer this resistance. AZD9291 (osimertinib, tagrisso) has been approved for treatment of the metastatic EGFR T790M mutation-positive non-small cell lung cancer. Resistance to AZD9291 has been described. C797S mutation was reported to be a major mechanism for resistance to T790M-targeting EGFR inhibitors. This review summarizes the latest development in identifying the C797S mutation and EAI045, the novel selective inhibitor overcoming the C797S mutant.